A controlled trial of percutaneous adrenal arterial embolization for hypertension in patients with idiopathic hyperaldosteronism

Intriguing review and topics in this month of Hypertension Research

“…Primary aldosteronism is one of important cause of resistant hypertension. In this issue, Zhou et al reported that percutaneous superselective adrenal arterial embolization provided the effective for blood pressure (BP) reduction compared with the treatment of mineralocorticoid receptor antagonists in treating patients with idiopathic hyperaldosteronism [9]. Although this treatment has not been generalized in clinical practice, it may be a promising treatment in the future.…”